{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T10:41:36Z","timestamp":1779014496657,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.jacl.2012.10.004","type":"journal-article","created":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T08:41:02Z","timestamp":1351586462000},"page":"14-23","source":"Crossref","is-referenced-by-count":7,"title":["Wax-matrix extended-release niacin vs inositol hexanicotinate: A comparison of wax-matrix, extended-release niacin to inositol hexanicotinate \u201cno-flush\u201d niacin in persons with mild to moderate dyslipidemia"],"prefix":"10.1016","volume":"7","author":[{"given":"Joseph M.","family":"Keenan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2012.10.004_bib1","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2337\/diacare.27.10.2444","article-title":"Increasing prevalence of metabolic syndrome among US adults","volume":"27","author":"Ford","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2012.10.004_bib2","first-page":"91","article-title":"The JUPITER trial: how will it change clinical practice?","volume":"10","author":"Watson","year":"2009","journal-title":"Rev Cardiol Med"},{"issue":"8 suppl","key":"10.1016\/j.jacl.2012.10.004_bib3","first-page":"s3","article-title":"Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting","volume":"14","author":"Cziraky","year":"2008","journal-title":"J Manage Care Pharm"},{"key":"10.1016\/j.jacl.2012.10.004_bib4","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/archinte.1991.00400070172024","article-title":"Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia","volume":"151","author":"Keenan","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2012.10.004_bib5","first-page":"313","article-title":"A clinical trial of oat bran and niacin in the treatment of hyperlipidemia","volume":"34","author":"Keenan","year":"1992","journal-title":"J Fam Pract"},{"key":"10.1016\/j.jacl.2012.10.004_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/archfami.5.10.567","article-title":"Clinical trial of wax-matrix sustained release niacin in a Russian population with hypercholesterolemia","volume":"5","author":"Aronov","year":"1996","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.jacl.2012.10.004_bib7","unstructured":"Endurance Products Company. Online catalog. Available at: http:\/\/www.endur.com. Accessed November 2,\u00a02012."},{"key":"10.1016\/j.jacl.2012.10.004_bib8","unstructured":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; NIH pub. No. 01\u20133670, May 2001. Available at: www.nhlbi.nih.gov\/guidelines\/cholesterol\/atp3xsum.pdf. Accessed November 2,\u00a02012."},{"key":"10.1016\/j.jacl.2012.10.004_bib9","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of the Niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2012.10.004_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0002-9149(89)90754-6","article-title":"Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol, and the cholesterol to high density lipoprotein ratio","volume":"64","author":"Alderman","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2012.10.004_bib11","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.2165\/00003495-200565180-00014","article-title":"Prolonged- release nicotinic acid: a review of its use in the treatment of dyslipidemia","volume":"65","author":"McCormack","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2012.10.004_bib12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archinte.164.10.1121","article-title":"Efficacy of extended-release niacin with lovastatin for hypercholesterolemia","volume":"164","author":"Insull","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2012.10.004_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1520-037X.2006.04736.x","article-title":"\u201cFlush-free\u201d niacin: dietary supplement may be \u201cbenefit free\u201d","volume":"9","author":"Norris","year":"2006","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.jacl.2012.10.004_bib14","first-page":"176","article-title":"Inositol hexanicotinate: a safer alternative to niacin","volume":"1","author":"Head","year":"1996","journal-title":"Alt Med Rev"},{"key":"10.1016\/j.jacl.2012.10.004_bib15","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.2146\/ajhp060089","article-title":"Dissolution profiles of non-prescription extended-release niacin and inositol niacinate products","volume":"63","author":"Poon","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacl.2012.10.004_bib16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/j.1552-4604.1988.tb05731.x","article-title":"Comparison of excretion of nicotinuric acid after ingestion of two controlled release nicotinic acid preparations in man","volume":"28","author":"Figge","year":"1988","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.jacl.2012.10.004_bib17","unstructured":"NIH News: National Heart, Lung and Blood Institute. NIH stops clinical trial on combination cholesterol treatment. Press release. Thur., May 26, 2011. Available at: http:\/\/www.nih.gov\/news\/health\/may2011\/nhlbi-26.htm. Accessed November 2,\u00a02012."},{"key":"10.1016\/j.jacl.2012.10.004_bib18","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2012.10.004_bib19","unstructured":"National Lipid Association. Further results of AIM-HIGH presented at the American Heart Association 2011 Scientific Sessions. Statement to National Lipid Association Members. Available at: http:\/\/www.lipid.org\/node\/70. Accessed November 2,\u00a02012."},{"key":"10.1016\/j.jacl.2012.10.004_bib20","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER-6 HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6: HDL and LDL Treatment Strategies in Atherosclerosis","volume":"55","author":"Villiness","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2012.10.004_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jacl.2009.04.052","article-title":"The SLIM study: slo-niacin and atorvastatin treatment of lipoproteins and inflammatory markers in combined hyperlipidemia","volume":"3","author":"Knopp","year":"2009","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2012.10.004_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0002-9149(99)80056-3","article-title":"Comparison of Lovastatin (20mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia","volume":"76","author":"Vacek","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2012.10.004_bib23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4065\/78.6.735","article-title":"Niacin as a component of combination therapy for dyslipidemia","volume":"78","author":"Miller","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2012.10.004_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4070\/kcj.2011.41.11.641","article-title":"The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis","volume":"41","author":"Lee","year":"2011","journal-title":"Korean Cir J"},{"key":"10.1016\/j.jacl.2012.10.004_bib25","unstructured":"ClinicalTrials.gov. HPS-2 THRIVE study description. Available at: www.clinicaltrials.gov\/ct2\/show\/NCT00461630. Accessed November 2,\u00a02012."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287412003777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287412003777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T18:58:30Z","timestamp":1542653910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287412003777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1933287412003777"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2012.10.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}